MCID: PLY020
MIFTS: 47

Polyradiculoneuropathy

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Polyradiculoneuropathy

MalaCards integrated aliases for Polyradiculoneuropathy:

Name: Polyradiculoneuropathy 12 54 44 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:4308
MeSH 44 D011129
SNOMED-CT 67 128078004
UMLS 70 C0032587

Summaries for Polyradiculoneuropathy

Disease Ontology : 12 A peripheral nervous system disease that is characterized by the co-occurance of polyneuropahty and polyradicuopathy and is located in both the spinal nerve roots and the peripheral nerves.

MalaCards based summary : Polyradiculoneuropathy is related to guillain-barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. An important gene associated with Polyradiculoneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Immunoglobulins and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, skin and endothelial, and related phenotypes are hematopoietic system and cellular

Wikipedia : 73 Polyradiculoneuropathy describes a condition in which polyneuropathy and polyradiculopathy occur... more...

Related Diseases for Polyradiculoneuropathy

Diseases in the Polyradiculoneuropathy family:

Chronic Polyradiculoneuropathy

Diseases related to Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 489)
# Related Disease Score Top Affiliating Genes
1 guillain-barre syndrome 31.9 PMP22 MPZ MBP IL17A ALB
2 chronic inflammatory demyelinating polyradiculoneuropathy 31.2 SH2D2A PMP22 MPZ MBP IL17A IL10
3 polyneuropathy 31.2 PMP22 MPZ MBP ALB
4 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.5 IL17A IL10 IFNG
5 hereditary neuropathies 30.5 PMP22 MPZ MBP
6 optic neuritis 30.4 MPZ MBP IL10
7 foot drop 30.3 PMP22 MPZ
8 neurosyphilis 30.3 IL17A IL10
9 myasthenia gravis 30.2 MBP IL10 IFNG
10 mononeuropathy 30.2 PMP22 MPZ ALB
11 transverse myelitis 30.1 MBP IL17A IL10
12 brucellosis 30.1 IL17A IL10 IFNG
13 chronic graft versus host disease 30.0 IL10 IFNG CCL5
14 allergic encephalomyelitis 30.0 MBP CCL5
15 exanthem 30.0 IL10 IFNG ALB
16 myelitis 29.9 TNFRSF1A MBP IL17A IL10
17 severe acute respiratory syndrome 29.9 IL10 IFNG CCL5
18 meningoencephalitis 29.9 MBP IL10 CCL5 ALB
19 neuritis 29.9 PMP22 MPZ MBP IL10 IFNG CCL5
20 hypertrophic neuropathy of dejerine-sottas 29.9 PMP22 MPZ MBP
21 thyroiditis 29.9 IL17A IL10 IFNG
22 chickenpox 29.8 IL10 IFNG ALB
23 metachromatic leukodystrophy 29.8 MPZ MBP ALB
24 hepatitis a 29.8 IL10 IFNG ALB
25 acquired immunodeficiency syndrome 29.8 TNFRSF1A MBP IL10 IFNG ALB
26 chorioretinitis 29.7 IL17A IL10 IFNG
27 chlamydia 29.6 IL17A IL10 IFNG
28 radiculopathy 29.6 IL17A IL10 CCL5 CCL4
29 cholangitis, primary sclerosing 29.6 IL17A IL10 ALB
30 acute disseminated encephalomyelitis 29.6 MPZ MBP IL10 CCL4
31 hashimoto thyroiditis 29.5 IL17A IL10 IFNG
32 encephalitis 29.5 IL10 CXCR4 CCL5 CCL4
33 dengue disease 29.5 IL10 IFNG CCL5 CCL4
34 dermatitis 29.5 IL17A IL10 IFNG CCL5
35 viral hepatitis 29.4 TNFRSF1A IL10 IFNG ALB
36 bacterial infectious disease 29.4 IL17A IL10 IFNG CCL4
37 crohn's disease 29.3 TNFRSF1A IL17A IL10 IFNG ALB
38 relapsing-remitting multiple sclerosis 29.3 TNFRSF1A MBP IL17A IL10 IFNG CCL5
39 type 1 diabetes mellitus 29.3 IL17A IL10 IFNG ALB
40 autoimmune disease 29.3 TNFRSF1A MBP IL17A IL10 IFNG CCL5
41 nervous system disease 29.3 MBP IL17A IL10 IFNG ALB
42 lung disease 29.2 IL17A IL10 IFNG CCL5 ALB
43 meningitis 29.2 IL17A IL10 IFNG CCL5 CCL4 ALB
44 dermatitis, atopic 29.1 IL17A IL10 IFNG CCL5 CCL4
45 uveitis 29.1 TNFRSF1A IL17A IL10 IFNG CCL4
46 psoriasis 29.0 TNFRSF1A IL17A IL10 IFNG CCL5
47 peripheral nervous system disease 28.9 PMP22 MPZ MBP IL17A IL10 IFNG
48 demyelinating disease 28.8 TNFRSF1A PMP22 MPZ MBP IL17A IL10
49 myeloma, multiple 28.8 IL10 CXCR4 CXCL12 ALB
50 secondary progressive multiple sclerosis 28.8 MBP IL17A IL10 IFNG CCL21 ALB

Graphical network of the top 20 diseases related to Polyradiculoneuropathy:



Diseases related to Polyradiculoneuropathy

Symptoms & Phenotypes for Polyradiculoneuropathy

MGI Mouse Phenotypes related to Polyradiculoneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CCL19 CCL21 CCL5 CXCL12 CXCR4 GATA2
2 cellular MP:0005384 10.02 ALB CXCL12 CXCR4 GATA2 IFNG IL10
3 immune system MP:0005387 9.97 ALB CCL19 CCL21 CCL5 CXCL12 CXCR4
4 muscle MP:0005369 9.5 ALB CXCL12 CXCR4 IFNG IL10 PMP22
5 reproductive system MP:0005389 9.28 CXCL12 CXCR4 GATA2 IFNG IL10 MBP

Drugs & Therapeutics for Polyradiculoneuropathy

Drugs for Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins Phase 4
2 Antibodies Phase 4
3 Immunoglobulins, Intravenous Phase 4
4 Immunologic Factors Phase 4
5 gamma-Globulins Phase 4
6 Rho(D) Immune Globulin Phase 4
7 Immunoglobulin G Phase 4
8
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
9
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
10 Fingolimod Hydrochloride Phase 3
11 Hormone Antagonists Phase 3
12 Hormones Phase 3
13 glucocorticoids Phase 3
14 Antineoplastic Agents, Hormonal Phase 3
15 Anti-Inflammatory Agents Phase 3
16 Pharmaceutical Solutions Phase 2, Phase 3
17
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
18
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
19
Carmustine Approved, Investigational Phase 2 154-93-8 2578
20
Etoposide Approved Phase 2 33419-42-0 36462
21
Melphalan Approved Phase 2 148-82-3 4053 460612
22
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
23
rituximab Approved Phase 2 174722-31-7 10201696
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25
Biotin Approved, Investigational, Nutraceutical Phase 2 58-85-5 171548
26
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
27
Cortisone Experimental Phase 2 53-06-5 222786
28
Rozanolixizumab Investigational Phase 2 1584645-37-3
29 Adjuvants, Immunologic Phase 2
30 interferons Phase 2
31 Interferon-beta Phase 2
32 Vitamin B9 Phase 2
33 Nutrients Phase 2
34 Trace Elements Phase 2
35 Vitamin B Complex Phase 2
36 Vitamins Phase 2
37 Folate Phase 2
38 Micronutrients Phase 2
39 Vitamin B7 Phase 2
40 Alpha-lipoic Acid Phase 2
41 Antioxidants Phase 2
42 Protective Agents Phase 2
43 Thioctic Acid Phase 2
44 Anti-Infective Agents Phase 2
45 Antiviral Agents Phase 2
46 Thymoglobulin Phase 2
47 Tubulin Modulators Phase 2
48 Etoposide phosphate Phase 2
49 Keratolytic Agents Phase 2
50 Dermatologic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting NCT03684018 Phase 4
3 Randomized, Parallel Study of Subcutaneous Versus Intravenous Immunoglobulin in Treatment-naïve Patients With Chronic Inflammatory Demyelinating Polyneuropathy Recruiting NCT04589299 Phase 4
4 An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
5 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
6 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
7 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
8 An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02293460 Phase 3 I10E
9 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
10 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
11 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
12 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
13 A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
14 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
15 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
16 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
17 Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02955355 Phase 3
18 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02549170 Phase 3
19 Double-blind, Placebo-controlled, Randomised, Multicentre, Adaptive, Two-stage Phase 2/3 Study Evaluating Safety and Efficacy of Three Dosages of NewGam in CIDP Patients Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
20 International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302" Terminated NCT02317562 Phase 3 I10E
21 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
22 Randomised, Double-blinded, Placebo-controlled Trial of Subcutaneous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
23 SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Completed NCT02967679 Phase 2 MD1003
24 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
25 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
26 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Completed NCT00278629 Phase 2
27 A Phase 2, Multicenter, Open-label, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04658472 Phase 2 BIVV020
28 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases Recruiting NCT00716066 Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan;Prednisone
29 Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04280718 Phase 2
30 A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04281472 Phase 2
31 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Active, not recruiting NCT03864185 Phase 2
32 A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Active, not recruiting NCT03861481 Phase 2 Rozanolixizumab
33 An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Enrolling by invitation NCT04051944 Phase 2 Rozanolixizumab
34 Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study Not yet recruiting NCT04480450 Phase 2 Rituximab
35 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
36 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
37 A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING TO HEALTHY ADULT MALE PARTICIPANTS Recruiting NCT03275740 Phase 1 PF-06755347 intravenous;Placebo intravenous;PF-06755347 subcutaneous;Placebo subcutaneous
38 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
39 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Unknown status NCT02892890
40 Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells Unknown status NCT02404298 IVIg
41 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858
42 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Unknown status NCT03397303
43 A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT02465359 Immune Globulin Subcutaneous (Human)
44 "Clinical Study of Intravenous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy" Completed NCT00305266 intravenous gammaglobulin
45 MRI of the Brachial Plexus and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Assessment of DTI-derived Measurements at 3.0-T Completed NCT03460951
46 Magnetic Resonance Imaging and Ultrasound Imaging of Peripheral Nerves in Patients Treated With Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02017769
47 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
48 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01379833
49 Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) Completed NCT02121678
50 The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN Completed NCT02111590 Immunoglobulins

Search NIH Clinical Center for Polyradiculoneuropathy

Cochrane evidence based reviews: polyradiculoneuropathy

Genetic Tests for Polyradiculoneuropathy

Anatomical Context for Polyradiculoneuropathy

MalaCards organs/tissues related to Polyradiculoneuropathy:

40
Spinal Cord, Skin, Endothelial, Tongue, Neutrophil, Bone, Nk Cells

Publications for Polyradiculoneuropathy

Articles related to Polyradiculoneuropathy:

(show top 50) (show all 1620)
# Title Authors PMID Year
1
Recurrent polyradiculoneuropathy and PMP22 defects. 54 61
16323394 2005
2
Reference values for lower limb nerve ultrasound and its diagnostic sensitivity. 61
33775342 2021
3
CIDP, CMT1B, or CMT1B plus CIDP? 61
33070202 2021
4
Immune-mediated neuromuscular complications of graft-versus-host disease. 61
33651380 2021
5
Creutzfeldt-Jakob Disease May Present Early With Unusual Bulbar Predominance. 61
33646993 2021
6
[Autologous hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyneuropathy]. 61
33773849 2021
7
Extraocular Muscle Enlargement and Proptosis Associated with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. 61
33795609 2021
8
Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: from intrinsic genetic background to clinical manifestations. 61
33782779 2021
9
The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy. 61
33752693 2021
10
Bioactive Glass in a Rare Case of Osteomyelitis of the Heel in a Guillain-Barré Syndrome: A Case Report. 61
31996063 2021
11
Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy. 61
33428052 2021
12
Dissociation of axo-glial junction in anti-neurofascin 155 chronic inflammatory demyelinating polyneuropathy. 61
33261722 2021
13
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS. 61
33093191 2021
14
Patients who meet electrodiagnostic criteria for CIDP rarely present with a sensory predominant DSP phenotype. 61
33745140 2021
15
[POEMS syndrome: Diagnosis, stratification, treatments]. 61
33678446 2021
16
Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. 61
33657260 2021
17
Contemporary Onset Of Atypical Chronic Inflammatory Demyelinating Polyradiculoneuropathy And Type 1 Diabetes In An Adolescent. 61
33772868 2021
18
Focal chronic inflammatory demyelinating polyradiculoneuropathy: Onset, course, and distinct features. 61
33660880 2021
19
Sonographic Multifocal Cranial Nerve Enlargement in Multifocal Acquired Demyelinating Sensory and Motor Neuropathy. 61
33746164 2021
20
Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs. 61
33106368 2021
21
High-Resolution Nerve Ultrasound Abnormalities in POEMS Syndrome-A Comparative Study. 61
33572067 2021
22
Is Guillain-Barrè syndrome triggered by SARS-CoV-2? Case report and literature review. 61
32643136 2021
23
Magnetic resonance neurography in diagnosing childhood chronic inflammatory demyelinating polyradiculoneuropathy. 61
33433331 2021
24
Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria? 61
32959475 2021
25
Post-traumatic (and postsurgical) Guillain-Barré Syndrome: a rare, but treatable entity. 61
33558381 2021
26
Chronic inflammatory demyelinating polyradiculoneuropathy associated with systemic lupus erythematosus. 61
33383292 2021
27
Juvenile Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology in Sardinia, Insular Italy. 61
33111308 2021
28
Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up. 61
33638679 2021
29
Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. 61
32909093 2021
30
Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC). 61
33608058 2021
31
Exertional Painless Weakness: Chronic Inflammatory Demyelinating Polyradiculoneuropathy in a Recreational Runner. 61
33560029 2021
32
Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach. 61
32914902 2021
33
Autologous hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. 61
33631093 2021
34
[Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors]. 61
33361512 2021
35
Chronic immune sensory polyradiculopathy (CISP): First juvenile case description. 61
32651857 2021
36
Treatment Approaches for Atypical CIDP. 61
33790853 2021
37
Patients' experiences and perceptions of Guillain-Barré syndrome: A systematic review and meta-synthesis of qualitative research. 61
33534851 2021
38
Severe Headache, Paraesthesias, Facial Diplegia and Pleocytosis: A Misleading Presentation of Guillain-Barré Syndrome. 61
33585341 2021
39
Guillain-Barré Syndrome in a COVID-19 Patient: A Case Report and Review of Management Strategies. 61
33553616 2021
40
Clinical and Electrophysiological Outcome Measures of Patients With Post-Infectious Neurological Syndromes Related to COVID-19 Treated With Intensive Neurorehabilitation. 61
33776896 2021
41
Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of 'long COVID-19 syndrome'? 61
33462068 2021
42
Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series. 61
33321326 2021
43
Encephalomyeloradiculoneuropathy Revealing a Rare Case of Intravascular Large B-Cell Lymphoma. 61
33614346 2021
44
Elevated levels of NLRP3 inflammasome in serum of patients with chronic inflammatory demyelinating polyradiculoneuropathy are associated with disease severity. 61
33409826 2021
45
Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy. 61
33460483 2021
46
Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy. 61
32876962 2021
47
Expression analysis of BDNF, BACE1 and their antisense transcripts in inflammatory demyelinating polyradiculoneuropathy. 61
33160139 2021
48
Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study. 61
33747132 2021
49
Update on therapy of chronic immune-mediated neuropathies. 61
33452933 2021
50
Guillain-Barré syndrome: clinical features, treatment choices and outcomes in an Australian cohort. 61
31760675 2020

Variations for Polyradiculoneuropathy

Expression for Polyradiculoneuropathy

Search GEO for disease gene expression data for Polyradiculoneuropathy.

Pathways for Polyradiculoneuropathy

Pathways related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 TNFRSF1A IL17A IL10 CXCR4 CXCL12 CCL5
2
Show member pathways
13.53 TNFRSF1A IL17A IL10 IFNG CXCR4 CXCL12
3
Show member pathways
13.37 TNFRSF1A IL17A IL10 IFNG CXCR4 CXCL12
4
Show member pathways
13.28 TNFRSF1A IL17A IL10 CXCR4 CXCL12 CCL5
5
Show member pathways
13.21 TNFRSF1A IL17A IL10 IFNG CCL5 CCL4
6
Show member pathways
13.04 TNFRSF1A IL17A IL10 CXCR4 CXCL12 CCL5
7
Show member pathways
12.8 TNFRSF1A CXCR4 CXCL12 CCL5 CCL4
8
Show member pathways
12.76 CXCR4 CXCL12 CCL5 CCL4 CCL21 CCL19
9
Show member pathways
12.69 IL17A IL10 IFNG CXCR4 CXCL12 CCL21
10
Show member pathways
12.28 IL10 IFNG CXCR4 CXCL12
11
Show member pathways
12.13 IL17A IL10 IFNG CXCL12
12 12.07 TNFRSF1A IL17A IL10 IFNG GATA2 CXCR4
13 11.8 PMP22 MPZ MBP
14 11.78 IL17A IFNG CXCL12 CCL5
15
Show member pathways
11.69 CXCL12 CCL21 CCL19
16 11.67 IL17A IL10 IFNG
17 11.67 TNFRSF1A CXCL12 CCL4 CCL21 CCL19
18
Show member pathways
11.63 IL17A IL10 IFNG
19 11.56 GATA2 CXCR4 CXCL12
20
Show member pathways
11.56 TNFRSF1A IL10 CXCR4 CXCL12 CCL5 CCL4
21 11.24 TNFRSF1A IL10 CCL5 CCL4 CCL19
22
Show member pathways
11.23 TNFRSF1A IL10 IFNG CCL4
23 11.2 CXCR4 CXCL12 CCL5
24 10.9 IL17A IL10 CXCL12 CCL5 CCL4 CCL21

GO Terms for Polyradiculoneuropathy

Cellular components related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNFRSF1A IL17A IL10 IFNG CXCL12 CCL5
2 extracellular space GO:0005615 9.32 TNFRSF1A IL17A IL10 IFNG CXCL12 CCL5

Biological processes related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 TNFRSF1A SH2D2A IL10 CXCR4 CXCL12 CCL5
2 G protein-coupled receptor signaling pathway GO:0007186 10.18 CXCR4 CXCL12 CCL5 CCL4 CCL21 CCL19
3 positive regulation of GTPase activity GO:0043547 10 CCL5 CCL4 CCL21 CCL19
4 cytokine-mediated signaling pathway GO:0019221 9.99 TNFRSF1A IL17A IL10 CCL5 CCL4 CCL19
5 inflammatory response GO:0006954 9.98 TNFRSF1A IL17A CXCR4 CCL5 CCL4 CCL21
6 cell-cell signaling GO:0007267 9.95 IL17A CCL5 CCL4 CCL21
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.94 CCL5 CCL4 CCL21 CCL19
8 cellular response to tumor necrosis factor GO:0071356 9.89 CCL5 CCL4 CCL21 CCL19
9 cellular calcium ion homeostasis GO:0006874 9.87 CXCL12 CCL5 CCL19
10 neuron migration GO:0001764 9.87 GATA2 CXCR4 CXCL12
11 cellular response to interferon-gamma GO:0071346 9.87 CCL5 CCL4 CCL21 CCL19
12 positive regulation of interleukin-6 production GO:0032755 9.85 MBP IL17A IFNG
13 response to toxic substance GO:0009636 9.85 MBP CCL5 CCL4
14 positive regulation of tumor necrosis factor production GO:0032760 9.84 IL17A IFNG CCL19
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 TNFRSF1A IFNG CCL5
16 neutrophil chemotaxis GO:0030593 9.84 CCL5 CCL4 CCL21 CCL19
17 positive regulation of interleukin-1 beta production GO:0032731 9.8 IL17A IFNG CCL19
18 monocyte chemotaxis GO:0002548 9.8 CCL5 CCL4 CCL21 CCL19
19 cell chemotaxis GO:0060326 9.8 CXCR4 CXCL12 CCL5 CCL21 CCL19
20 positive regulation of interleukin-12 production GO:0032735 9.79 IL17A IFNG CCL19
21 cell maturation GO:0048469 9.77 GATA2 CCL21 CCL19
22 cellular response to interleukin-1 GO:0071347 9.77 IL17A CCL5 CCL4 CCL21 CCL19
23 lymphocyte chemotaxis GO:0048247 9.76 CCL5 CCL4 CCL21 CCL19
24 positive regulation of chemotaxis GO:0050921 9.73 CXCR4 CCL21 CCL19
25 chemotaxis GO:0006935 9.73 CXCR4 CXCL12 CCL5 CCL4 CCL21 CCL19
26 eosinophil chemotaxis GO:0048245 9.72 CCL5 CCL4 CCL21
27 chemokine-mediated signaling pathway GO:0070098 9.72 CXCL12 CCL5 CCL4 CCL21 CCL19
28 cellular response to chemokine GO:1990869 9.71 CXCL12 CCL21
29 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.71 CXCR4 CXCL12
30 positive regulation of T cell chemotaxis GO:0010820 9.7 CCL5 CCL21
31 positive regulation of T cell migration GO:2000406 9.7 CXCL12 CCL5 CCL21
32 detection of mechanical stimulus involved in sensory perception of pain GO:0050966 9.69 CXCR4 CXCL12
33 positive regulation of signaling receptor activity GO:2000273 9.69 IL10 IFNG
34 negative regulation by host of viral transcription GO:0043922 9.68 CCL5 CCL4
35 immunological synapse formation GO:0001771 9.68 CCL21 CCL19
36 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL10 IFNG
37 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.67 MBP IL10
38 response to prostaglandin E GO:0034695 9.66 CCL21 CCL19
39 establishment of T cell polarity GO:0001768 9.65 CCL21 CCL19
40 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.65 CCL21 CCL19
41 negative regulation of dendritic cell apoptotic process GO:2000669 9.65 CXCL12 CCL21 CCL19
42 positive regulation of natural killer cell chemotaxis GO:2000503 9.64 CCL5 CCL4
43 telencephalon cell migration GO:0022029 9.63 CXCR4 CXCL12
44 positive regulation of interleukin-23 production GO:0032747 9.62 IL17A IFNG
45 negative regulation of leukocyte tethering or rolling GO:1903237 9.62 CXCL12 CCL21
46 positive regulation of glycoprotein biosynthetic process GO:0010560 9.61 CCL21 CCL19
47 response to ultrasound GO:1990478 9.58 CXCR4 CXCL12
48 dendritic cell chemotaxis GO:0002407 9.46 CXCR4 CCL5 CCL21 CCL19
49 response to virus GO:0009615 9.43 IFNG CXCR4 CXCL12 CCL5 CCL4 CCL19
50 immune response GO:0006955 9.32 MBP IL17A IL10 IFNG CXCR4 CXCL12

Molecular functions related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.56 CCL5 CCL4 CCL21 CCL19
2 chemokine activity GO:0008009 9.55 CXCL12 CCL5 CCL4 CCL21 CCL19
3 CCR5 chemokine receptor binding GO:0031730 9.4 CCL5 CCL4
4 CCR1 chemokine receptor binding GO:0031726 9.37 CCL5 CCL4
5 CCR7 chemokine receptor binding GO:0031732 9.32 CCL21 CCL19
6 chemokine receptor binding GO:0042379 9.26 CXCL12 CCL5 CCL21 CCL19
7 cytokine activity GO:0005125 9.23 IL17A IL10 IFNG CXCL12 CCL5 CCL4

Sources for Polyradiculoneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....